PT001 MDI Versus Spiriva® in Patients With Moderate to Severe COPD
NCT01566773
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
140
Enrollment
INDUSTRY
Sponsor class
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
DRUG:
PT001 MDI
DRUG:
Tiotropium Bromide
DRUG:
PT001 Placebo MDI
Sponsor
Pearl Therapeutics, Inc.